Welcome to our dedicated page for Kyverna Therapeutics news (Ticker: KYTX), a resource for investors and traders seeking the latest updates and insights on Kyverna Therapeutics stock.
Kyverna Therapeutics develops cell therapies for autoimmune diseases, with a focus on CD19-targeting CAR T approaches. The company's recurring news centers on miv-cel, also known as mivocabtagene autoleucel or KYV-101, an autologous CAR T-cell therapy candidate being studied across B-cell-driven autoimmune diseases.
Company updates commonly cover clinical data from the KYSA neuroimmunology program, including stiff person syndrome and generalized myasthenia gravis, as well as additional autoimmune indications such as multiple sclerosis and rheumatoid arthritis. Kyverna also reports business and financial results, medical-meeting presentations, board and executive appointments, and commercial leadership developments tied to its transition from clinical development toward potential product launch activity.
Kyverna Therapeutics (Nasdaq: KYTX) appointed Greg Martini as Chief Financial Officer effective May 18, 2026, succeeding Dr. Marc Grasso, who will consult during the transition. Martini will lead financial strategy as Kyverna advances its CAR T candidate miv-cel (KYV-101) toward potential approval in stiff person syndrome and a planned commercial transition.
Kyverna will grant Martini an inducement option for 325,000 shares, vesting over four years under its 2024 Inducement Equity Incentive Plan.
Kyverna Therapeutics (Nasdaq: KYTX) announced that management will present at two upcoming investor conferences: the H.C. Wainwright 4th Annual Nasdaq BioConnect Conference on May 19, 2026 at 2:30 p.m. ET and the Jefferies Global Healthcare Conference on June 3, 2026 at 3:10 p.m. ET. Live webcasts and 90-day replays will be available in the Investors section of Kyverna’s website.
Kyverna Therapeutics (Nasdaq: KYTX) initiated a rolling BLA submission for miv-cel in stiff person syndrome (SPS) after FDA alignment that single-arm Phase 2 KYSA-8 data can support filing. KYSA-8 showed statistically significant, durable benefits with patients off SPS immunotherapies at 16 weeks.
Enrollment continues in the Phase 3 KYSA-6 trial in generalized myasthenia gravis with one-year Phase 2 follow-up indicating durable responses. Updated Phase 1 data in progressive multiple sclerosis showed disability improvement or stability and favorable safety. Kyverna appointed Nadia Dac as CCO and reported Q1 2026 cash of $236.4 million, expecting runway into 2028 and a net loss of $39.7 million.
Kyverna Therapeutics (Nasdaq: KYTX) appointed Nadia Dac as Chief Commercial Officer effective May 4, 2026. Ms. Dac has more than 30 years of commercial leadership and will lead strategy and execution for miv-cel (KYV-101), positioned for a potential first approval in stiff person syndrome. Kyverna granted a 300,000-share option as an inducement, vesting over four years, with exercise price set at the closing stock price on the grant date.
Kyverna (NASDAQ: KYTX) reported positive registrational KYSA-8 results for miv-cel in stiff person syndrome (SPS), with a single dose showing statistically significant, durable benefit and a manageable safety profile.
Key results: T25FW improved median 46% (Week 16, p=0.0003); 81% had ≥20% improvement; all 26 patients discontinued chronic immunotherapies through last follow-up; no high-grade CRS or ICANS observed.
Kyverna Therapeutics (NASDAQ: KYTX) reported longer-term Phase 2 KYSA-6 data for miv-cel in generalized myasthenia gravis showing deep, durable responses after a single 1×10^8 dose.
All seven patients achieved clinically meaningful MG-ADL and QMG improvements at 24 weeks; mean reductions were -8.5 MG-ADL and -11.3 QMG. Responses were sustained to 52 weeks in three patients. No high-grade CRS or ICANS observed; two transient grade 3/4 neutropenias resolved. The trial is enrolled into an FDA-aligned Phase 2/3 registrational design.
Kyverna Therapeutics (Nasdaq: KYTX) will host a conference call on April 22, 2026 at 7:00 a.m. ET to review primary analysis from the KYSA-8 registrational trial of miv-cel (KYV-101) in stiff person syndrome and longer-term follow-up from KYSA-6 in generalized myasthenia gravis.
Data are being presented orally and as posters at the American Academy of Neurology Annual Meeting, April 18-22, 2026 in Chicago. The call requires registration and will be available via live webcast and archived replay on Kyverna's Investor Relations site.
Kyverna Therapeutics (NASDAQ: KYTX) reported fourth-quarter and full-year 2025 results and a business update focused on its autoimmune CAR T candidate miv-cel (KYV-101). The company expects a BLA submission in 1H 2026, plans a commercial launch by year-end 2026, and reports $279.3 million cash runway into 2028 to fund launch and Phase 3 gMG.
Key clinical highlights include statistically significant SPS registrational topline results, positive interim KYSA-6 gMG data with Phase 3 enrollment started, and encouraging investigator-led PMS and RA results. Full-year net loss was $161.3 million.
Kyverna Therapeutics (NASDAQ: KYTX) will present new neuroimmunology data at the American Academy of Neurology (AAN) Annual Meeting, April 18-22, 2026 in Chicago.
Oral sessions include primary analysis from the registrational KYSA-8 trial in stiff person syndrome showing statistically significant clinical benefit and updated KYSA-6 Phase 2 results in generalized myasthenia gravis. Multiple posters cover real-world outcomes and Phase 3 design.
Kyverna Therapeutics (Nasdaq: KYTX) announced management will attend investor conferences in March 2026, including a Leerink fireside chat and Jefferies investor meetings.
The Leerink fireside chat is scheduled for March 9, 2026 at 11:20 a.m. ET; a live webcast and a 90-day replay will be available via the company investor website, according to the company.